- Home
- XLO vs DXR Comparison
XLO vs DXR Comparison
Compare XLO & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XLO | DXR |
|---|---|---|
| Founded | 2016 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.9M | 59.0M |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | XLO | DXR |
|---|---|---|
| Price | $9.15 | $10.65 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $28.00 | N/A |
| AVG Volume (30 Days) | ★ 41.9K | 1.9K |
| Earning Date | 05-14-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,766,000.00 | $1,446,345.00 |
| Revenue This Year | N/A | $44,935.22 |
| Revenue Next Year | $168.77 | $74.79 |
| P/E Ratio | ★ N/A | $33.83 |
| Revenue Growth | ★ 589.88 | N/A |
| 52 Week Low | $0.46 | $8.56 |
| 52 Week High | $9.89 | $14.76 |
Technical Indicators
Market Signals| Indicator | XLO | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 55.21 | 52.83 |
| Support Level | $7.47 | $9.79 |
| Resistance Level | $9.89 | $10.91 |
| Average True Range (ATR) | 0.39 | 0.42 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 76.24 | 27.49 |
Price Performance
Historical ComparisonAbout XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.